PRFX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:00):
Our systems believe the stock currently is overvalued by -0.05% compare to its pairs and should correct downwards.

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel...

Stats
Today's Volume	74 863
Average Volume	247 380
Market Cap	1.19M
EPS	$-2.72 ( Q1 \| 2024-05-15 )
Next earnings date	( $-1.040 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600 (Sector) 42.63 (Industry) 30.78
ATR14	$0.00300 (0.63%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Correlation (AI algo v.1.1b): Overvalued: -0.05% $0.480 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.27 (neutral)

Short: -0.82 (strong negative)

Signal:(50.599) Neutral

PainReform Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PainReform Ltd. Correlation - Currency/Commodity

-0.21
( neutral )

0.00
( neutral )

0.25
( neutral )

PainReform Ltd. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-15 000.00 (0.00 %)
EPS:	$-7.14

FY	2023
Revenue:	$0
Gross Profit:	$-15 000.00 (0.00 %)
EPS:	$-7.14

FY	2022
Revenue:	$86 000.00
Gross Profit:	$71 000.00 (82.56 %)
EPS:	$-8.25

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.720

Financial Reports:

No articles found.

PainReform Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

PainReform Ltd.

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.